By Justin M. Watts, MD; Peter Maslak, MD; Martin S. Tallman, MD A 47-year-old woman presented for evaluation of pancytopenia. She had been diagnosed with papillary thyroid cancer 18 months earlier and underwent total thyroidectomy followed by radioiodine (I-131) ablation for nodal and small pulmonary metastases. Cumulative dose of radioactive iodine was 312 mCi. She…
By Barbara Ann Burtness, MD A 52-year-old man who lives in the Midwest presents with a lesion in his nose. He has an extensive history of sun exposure and a 35 pack-year smoking history. The patient sought attention from an otolaryngologist, who cultured the lesion in the right upper medial nasal vestibule but noted “no…
This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatment of advanced stage or recurrent endometrial cancer.
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Steven J. Cohen, MD, CTA Advisory Board member highlights key science from the 2015 Gastrointestinal Cancer Symposium.
CTA Advisory Board member, Neal Shore, MD, puts CHAARTED trial results into context.
Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.
Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
Dr. Dizon and patient advocate Katherine O’Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.
